Fully grasp their willingness or hesitations towards engaging in the behavior of dispensing methadone for OUD treatment. Objectives: (1) Discover neighborhood pharmacists’ attitudes and beliefs regarding dispensing methadone for OUD treatment in neighborhood pharmacies. (2) Capture the community pharmacist viewpoint of how dispensing methadone would have an effect on their practice. Procedures: Participants might be recruited through a College of Pharmacy’s neighborhood pharmacy preceptor database containing 182 actively practicing neighborhood pharmacists. This crosssectional survey might be distributed weekly for four weeks. The survey instrument includes demographic concerns and queries exploring attitudes and perceptions towards dispensing methadone for OUD treatment. Topic regions toType: Perform in Progress. Background: Bipolar disorder (BD) is actually a debilitating psychiatric disorder that can considerably impair one’s social and occupational function if inadequately treated. PPAR Purity & Documentation Whilst lithium is perhaps probably the most well-studied medication in the remedy of BD, lamotrigine is an option mood stabilizer which has shown to become well-tolerated and efficient for bipolar depression and prevention of mania. Nevertheless, simply because lamotrigine has not been shown to be powerful towards minimizing acute symptoms of mania or hypomania and calls for a slower titration as a result of risk of skin rash, Stevens-Johnson syndrome, and toxic epidermal necrolysis, lamotrigine might be underutilized in comparison to lithium. Understanding clinical predictors in individuals who respond well to lamotrigine and reasons for its discontinuation will aid with clinical selection making and potentially decrease time towards finding and optimizing pharmacologic remedy. Objectives: (1) Determine variables linked with lamotrigine response. (two) Assess factors for lamotrigine discontinuation. Solutions: This retrospective chart evaluation study incorporates veterans aged 18 years or older with a diagnosis of BD who received a lamotrigine prescription among October 1, 2017 and July 1, 2019. Patients are excluded from the study if they have any on the following comorbid psychiatric diagnoses: main depressive disorder, schizophrenia, or schizoaffective disorder. Sufferers with an active prescription for lamotrigine, consistently applied for at the least six weeks, and chart documentation of symptom reduction are categorized as responders. The motives for lamotrigine discontinuation are collected in non-responders. Predictor covariates that are examined contain demographic (age, gender, race) and clinical facts (comorbid psychiatric diagnoses; illness severity primarily based on past hospitalizations; mood state [depressed, manic, or hypomanic]; BD subtype [I, II, or unspecified]; presence of psychotic symptoms; substanceMent Health Clin [Internet]. 2021;11(two):75-172. DOI: ten.9740/mhc.2021.03.use history; and concurrent use of antidepressants, mood stabilizers, benzodiazepines, or antipsychotics) at initiation of lamotrigine. Logistic regression analysis might be made use of to examine the association of covariates with lamotrigine response. Outcomes: This study could help ascertain clinical predictors related with therapy response in lamotrigine use. Final results may possibly support guide our treatment MMP-13 Purity & Documentation approach, particularly with lamotrigine’s spot in BD therapy, and figure out which patient populations might advantage most from its use.Influence of a Pharmacist Driven Diabetes Monitoring Service in an Acute Psychiatric County FacilityAna Barron, PharmD1; Niyati Buta.